United States - English - NLM (National Library of Medicine)

mwi/vet one - bismuth subsalicylate (unii: 62tey51rr1) (salicylic acid - unii:o414pz4lpz) - bismuth subsalicylate 17.4 g in 1 l - suspension anti-diarrheal liquid a palatable oral suspension for use as an aid in controlling simple diarrhea in cattle, horses, dogs and cats.

United States - English - NLM (National Library of Medicine)

mwi/vetone - bismuth subsalicylate (unii: 62tey51rr1) (bismuth cation - unii:zs9cd1i8ye) - bismuth subsalicylate 18 mg in 1 ml - a palatable oral suspension for use as an aid in controlling simple diarrhea in cattle, horses, dogs and cats

United States - English - NLM (National Library of Medicine)

aspen veterinary - bismuth subsalicylate (unii: 62tey51rr1) (bismuth cation - unii:zs9cd1i8ye) - bismuth subsalicylate 18 mg in 1 ml - a palatable oral suspension for use as an aid in controlling simple diarrhea in cattle, horses, dogs and cats. store at controlled room temperature not above 37ºc (98.6ºf).  restricted drug. use only as directed. not for human use. take time observe label directions lot no.           exp. date

United States - English - NLM (National Library of Medicine)

american animal health, inc. - bismuth subsalicylate (unii: 62tey51rr1) (bismuth subsalicylate - unii:62tey51rr1) - bismuth subsalicylate 0.0175 mg in 1 ml

United States - English - NLM (National Library of Medicine)

marc glassman, inc. - bismuth subsalicylate (unii: 62tey51rr1) (salicylic acid - unii:o414pz4lpz) - bismuth subsalicylate 262 mg - antidiarrheal/antacid ■ controls diarrhea    ■ relieves heartburn, indigestion, nausea and upset stomach

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori  has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may

Israel - English - Ministry of Health

cts chemical industries ltd, israel - bismuth subsalicylate - suspension - bismuth subsalicylate 262 mg / 15 ml - bismuth subcitrate - bismuth subcitrate - relief of diarrhea, nausea, flatulence, convulsive stomach pains, uspet stomach. as a preventative treatment of traveler's diarrhea.

Israel - English - Ministry of Health

perrigo israel agencies ltd - bismuth sub salicylate 262 mg - chewable tablets - bismuth subcitrate - for relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.

Israel - English - Ministry of Health

perrigo israel agencies ltd, israel - bismuth subsalicylate - chewable tablets - bismuth subsalicylate 262 mg - bismuth subcitrate - bismuth subcitrate - for relief of diarrhea, nausea, flatulence, abdominal cramps, upset stomach and indigestion.